Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

PD-L1 inhibitors

- PMLiVE

Boehringer breaks into oncology with FDA approval

Agency backs company's first cancer drug afatinib in lung cancer

- PMLiVE

Setback for Merck & Co as FDA knocks back insomnia drug

US regulator asks for company to file for approval of a lower starting dose of suvorexant

- PMLiVE

US increases pressure on India over generics industry

Follows complaints from Pfizer about the country’s patent laws

- PMLiVE

Merck wins injunction against Januvia generics in India

Court blocks Aprica from launching copycat diabetes drug

- PMLiVE

BMS appoints Dinesh Paliwal to board

He is CEO of audio firm Harman International

- PMLiVE

Setback for AZ and BMS as Onglyza flunks cardiovascular trial

Diabetes drug fails to show benefit over placebo

- PMLiVE

Elotuzumab on track for multiple myeloma

BMS and AbbVie present phase II results at European Haematology Association meeting

- PMLiVE

BMS partners with Simcere to market arthritis drug Orencia SC in China

Builds on existing cancer/ cholesterol alliance between pharma companies

- PMLiVE

Partial victory for biotech sector after gene patent ruling

US Supreme Court decides genes can be patented, if synthetically produced

- PMLiVE

NICE knocks back Lilly’s Alimta in new setting

Institute not recommending Lilly’s lung cancer drug for new licence extension

- PMLiVE

FDA gives priority review status to BMS/ AZ’s metreleptin

Former obesity prospect has potential in the rare disease lipodystrophy

- PMLiVE

ASCO: Merck and BMS trumpet melanoma trials

Positive study results for anti-PD-1 candidates lambrolizumab and nivolumab

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links